NASDAQ:KITE - (KITE) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$179.79
+0 (0.00%)
Get New (KITE) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KITE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KITE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (KITE) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $179.79.

This chart shows the closing price for KITE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in (KITE). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017WedbushUpgradeUnderperform ➝ NeutralLow
8/28/2017GuggenheimDowngradeBuy ➝ Neutral$128.00Low
8/28/2017SunTrust BanksDowngradeBuy ➝ HoldMedium
8/28/2017BTIG ResearchDowngradeBuy ➝ NeutralHigh
8/10/2017Stifel NicolausReiterated RatingHold$74.00Low
8/9/2017Jefferies Financial GroupReiterated RatingBuy$121.00 ➝ $135.00Low
7/13/2017Maxim GroupDowngradeBuy ➝ Hold$88.00Low
7/10/2017Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$101.00 ➝ $121.00Medium
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/5/2022

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
(KITE) logo
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).
Read More

Today's Range

Now: $179.79
Low: $179.79
High: $179.79

50 Day Range

MA: N/A

52 Week Range

Now: $179.79
Low: $39.82
High: $179.99

Volume

N/A

Average Volume

1,652,408 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (KITE)?

The following Wall Street analysts have issued reports on (KITE) in the last year:
View the latest analyst ratings for KITE.

What is the current price target for (KITE)?

0 Wall Street analysts have set twelve-month price targets for (KITE) in the last year.
View the latest price targets for KITE.

What is the current consensus analyst rating for (KITE)?

(KITE) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KITE.

How do I contact (KITE)'s investor relations team?

(KITE)'s physical mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company's listed phone number is +1-310-8249999. The official website for (KITE) is www.kitepharma.com. Learn More about contacing (KITE) investor relations.